These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 25853461)

  • 1. Implementing quality by design for biotech products: Are regulators on track?
    Luciani F; Galluzzo S; Gaggioli A; Kruse NA; Venneugues P; Schneider CK; Pini C; Melchiorri D
    MAbs; 2015; 7(3):451-5. PubMed ID: 25853461
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Roadmap for implementation of quality by design (QbD) for biotechnology products.
    Rathore AS
    Trends Biotechnol; 2009 Sep; 27(9):546-53. PubMed ID: 19647883
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Summary of the EMA Joint Regulators/Industry QbD workshop (London, UK; 28-29 January 2014).
    Cook G; France G; Holte Ø; Lorenti G; Tainsh D
    PDA J Pharm Sci Technol; 2016; 70(2):163-76. PubMed ID: 26797977
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quality by design (QbD) approach in marketing authorization procedures of Non-Biological Complex Drugs: A critical evaluation.
    Zagalo DM; Sousa J; Simões S
    Eur J Pharm Biopharm; 2022 Sep; 178():1-24. PubMed ID: 35908664
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Implementation of Quality by Design (QbD) Principles in Regulatory Dossiers of Medicinal Products in the European Union (EU) Between 2014 and 2019.
    Ter Horst JP; Turimella SL; Metsers F; Zwiers A
    Ther Innov Regul Sci; 2021 May; 55(3):583-590. PubMed ID: 33439461
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Note for guidance. Production and quality control of human monoclonal antibodies. Committee for Proprietary Medicinal Products: Ad hoc Working Party on Biotechnology/Pharmacy and Working Party on Safety Medicines.
    Biologicals; 1991 Apr; 19(2):133-8. PubMed ID: 1888492
    [No Abstract]   [Full Text] [Related]  

  • 7. [The use of nanotechnology in medicinal products in the light of European Union law].
    Jurewicz M
    Pol Merkur Lekarski; 2014 Dec; 37(222):369-72. PubMed ID: 25715580
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Special considerations concerning regulatory requirements and drug development for peptides and biotech products in the EU.
    Braun A; Gassmann R; Kraus K; Lorenzi G; Weigel U
    Pharm Acta Helv; 1996 Dec; 71(6):447-58. PubMed ID: 8997177
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Report from the Committee for Advanced Therapies (CAT). Pitfalls on the way from concept to medical treatment with advanced therapy medicinal products].
    Reiss M; Büttel IC; Schneider CK
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2011 Jul; 54(7):822-30. PubMed ID: 21698535
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Note for guidance. Production and quality control of cytokine products derived by biotechnological processes. Committee for Proprietary Medicinal Products: Ad hoc Working Party on Biotechnology/Pharmacy and Working Party on Safety Medicines.
    Biologicals; 1991 Apr; 19(2):125-31. PubMed ID: 1888491
    [No Abstract]   [Full Text] [Related]  

  • 11. Adaptation of the quality by design concept in early pharmaceutical development of an intranasal nanosized formulation.
    Pallagi E; Ambrus R; Szabó-Révész P; Csóka I
    Int J Pharm; 2015 Aug; 491(1-2):384-92. PubMed ID: 26134895
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The legal framework governing the quality of (traditional) herbal medicinal products in the European Union.
    Kroes BH
    J Ethnopharmacol; 2014 Dec; 158 Pt B():449-53. PubMed ID: 25086408
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Knowledge management in the QbD paradigm: manufacturing of biotech therapeutics.
    Herwig C; Garcia-Aponte OF; Golabgir A; Rathore AS
    Trends Biotechnol; 2015 Jul; 33(7):381-7. PubMed ID: 25980924
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of raw materials in biopharmaceutical manufacturing: risk analysis and fingerprinting.
    Rathore AS; Kumar D; Kateja N
    Curr Opin Biotechnol; 2018 Oct; 53():99-105. PubMed ID: 29306677
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quality by Design: Concept to Applications.
    Swain S; Parhi R; Jena BR; Babu SM
    Curr Drug Discov Technol; 2019; 16(3):240-250. PubMed ID: 29521238
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Question-based review for pharmaceutical development: An enhanced quality approach.
    Simões A; Veiga F; Vitorino C
    Eur J Pharm Biopharm; 2024 Feb; 195():114174. PubMed ID: 38160986
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quality by Design: Development of the Quality Target Product Profile (QTPP) for Semisolid Topical Products.
    Namjoshi S; Dabbaghi M; Roberts MS; Grice JE; Mohammed Y
    Pharmaceutics; 2020 Mar; 12(3):. PubMed ID: 32210126
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quality Issues Identified During the Evaluation of Biosimilars by the European Medicines Agency's Committee for Medicinal Products for Human Use.
    Cilia M; Ruiz S; Richardson P; Salmonson T; Serracino-Inglott A; Wirth F; Borg JJ
    AAPS PharmSciTech; 2018 Feb; 19(2):489-511. PubMed ID: 29027130
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Determination of critical quality attributes for monoclonal antibodies using quality by design principles.
    Alt N; Zhang TY; Motchnik P; Taticek R; Quarmby V; Schlothauer T; Beck H; Emrich T; Harris RJ
    Biologicals; 2016 Sep; 44(5):291-305. PubMed ID: 27461239
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Towards the implementation of quality by design to the production of therapeutic monoclonal antibodies with desired glycosylation patterns.
    del Val IJ; Kontoravdi C; Nagy JM
    Biotechnol Prog; 2010; 26(6):1505-27. PubMed ID: 20665659
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.